(Q57583335)

English

Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies

article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20975664%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20975664%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1 reference

based on heuristic

inferred from title

supporting evidence

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

Charles-Antoine Dutertre

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20975664%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Hélène Merle-Béral

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20975664%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

author name string

M Le Garff-Tavernier

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20975664%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

J Decocq

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20975664%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

C de Romeuf

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20975664%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

C Parizot

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20975664%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

E Chapiro

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20975664%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

F Davi

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20975664%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

P Debré

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20975664%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

J F Prost

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20975664%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

J L Teillaud

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20975664%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

V Vieillard

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20975664%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

publication date

26 October 2010

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20975664%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20975664%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

25

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20975664%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20975664%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

101-109

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20975664%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.240

21 January 2018

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.240

21 January 2018

From the bench to the bedside: ways to improve rituximab efficacy.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.240

21 January 2018

Engineered antibody Fc variants with enhanced effector function

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.240

21 January 2018

Emerging therapies for patients with advanced chronic lymphocytic leukaemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.240

21 January 2018

Molecular and cellular mechanisms of CLL: novel therapeutic approaches.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.240

21 January 2018

Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.240

21 January 2018

M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.240

21 January 2018

Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.240

21 January 2018

Human natural killer cell development

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.240

21 January 2018

Functions of natural killer cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.240

21 January 2018

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.240

21 January 2018

Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.240

21 January 2018

Discrepancy between phenotypic and functional features of natural killer T-lymphocytes in B-cell chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.240

21 January 2018

Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.240

21 January 2018

Prognostic markers in chronic lymphocytic leukemia: a comprehensive review

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.240

21 January 2018

Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.240

21 January 2018

NK cell receptors and their ligands in leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.240

21 January 2018

Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.240

21 January 2018

Resistance of chronic lymphocytic leukaemia cells to interferon-alpha generated lymphokine activated killer cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.240

21 January 2018

Chronic lymphocytic leukemia: revelations from the B-cell receptor.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.240

21 January 2018

Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.240

21 January 2018

Disruption of T cell suppression in chronic lymphocytic leukemia by CD200 blockade

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.240

21 January 2018

Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.240

21 January 2018

Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.240

21 January 2018

Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.240

21 January 2018

FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.240

21 January 2018

Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.240

21 January 2018

The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.240

21 January 2018

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.240

21 January 2018

Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.240

7 January 2021

based on heuristic

inferred from DOI database lookup

Restoration of impaired natural killer cell activity of B-chronic lymphocytic leukemia patients by recombinant interleukin-2

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.240

7 January 2021

based on heuristic

inferred from DOI database lookup

Fully functional NK cells after unrelated cord blood transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.240

7 January 2021

based on heuristic

inferred from DOI database lookup

HLA antigens in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.240

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased frequency of homozygosity for HLA class II loci in female patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.240

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab dose-escalation trial in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.240

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2010.240

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20975664%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20975664%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57583335&oldid=2222093371"